JP2008013440A - Orally administering type beautifully whitening agent - Google Patents

Orally administering type beautifully whitening agent Download PDF

Info

Publication number
JP2008013440A
JP2008013440A JP2006183126A JP2006183126A JP2008013440A JP 2008013440 A JP2008013440 A JP 2008013440A JP 2006183126 A JP2006183126 A JP 2006183126A JP 2006183126 A JP2006183126 A JP 2006183126A JP 2008013440 A JP2008013440 A JP 2008013440A
Authority
JP
Japan
Prior art keywords
extract
whitening agent
orally administering
beautifully whitening
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006183126A
Other languages
Japanese (ja)
Inventor
Keiichi Matsuura
敬一 松浦
Hirotaka Ono
裕香 小野
Kiyoshi Iwashima
浄 岩嶋
Shoji Imai
昇治 今井
Yukitaka Fukaya
幸隆 深谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MATSURA YAKUGYO KK
Matsuura Yakugyo Co Ltd
Original Assignee
MATSURA YAKUGYO KK
Matsuura Yakugyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MATSURA YAKUGYO KK, Matsuura Yakugyo Co Ltd filed Critical MATSURA YAKUGYO KK
Priority to JP2006183126A priority Critical patent/JP2008013440A/en
Publication of JP2008013440A publication Critical patent/JP2008013440A/en
Withdrawn legal-status Critical Current

Links

Images

Landscapes

  • Cosmetics (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a beautifully whitening agent capable of widely improving the beautifully whitening effect by oral ingestion. <P>SOLUTION: This orally administering type agent comprises at least 1 kind of plant powder, an extract or a roughly purified product of the extract selected from the plants containing thalidroside as an active ingredient. This orally administering type beautifully whitening agent can inhibit pigment deposition by the oral administration, and exhibits effects against sunburn, spots and freckles by internal ingestion. Since substances derived from herbal medicines are used as active ingredients, side effects are relatively less and it is possible to administer the same for a long period. <P>COPYRIGHT: (C)2008,JPO&INPIT

Description

本発明は、内服することにより紫外線による色素沈着を抑制し、日焼け・シミ・ソバカスを改善する経口投与型美白剤に関するものである。   The present invention relates to an orally-administered whitening agent that suppresses pigmentation due to ultraviolet rays when taken orally and improves sunburn, spots, and freckles.

日焼け・シミ・ソバカスは女性にとって肌に関連する大きな関心事であり、常に若々しく美しい色白の肌が求められている。このシミ・ソバカスの色調の由来は主に皮膚に沈着するメラニン色素であり、この色素沈着の発生機序としては、メラノサイトおよびメラニンの増加、メラニン顆粒の授受障害、***障害等が挙げられている。従って、美白に関する基礎研究はメラノサイトの発生過程、メラノサイトの活性化を制御する生体内因子、メラノサイト内のメラニン生成機序に関する視点で行われており、様々なアプローチで美白剤が開発されつつある。   Sunburn, stains and freckles are a major skin-related concern for women, and there is always a need for youthful and beautiful skin. The origin of the color of this stain / buckwheat is melanin pigment deposited mainly on the skin, and the mechanisms of pigmentation include increased melanocytes and melanin, melanin granule delivery and excretion disorders, etc. . Therefore, basic research on whitening is performed from the viewpoints of melanocyte generation process, in vivo factors that control melanocyte activation, and melanin production mechanism in melanocytes, and whitening agents are being developed by various approaches.

近年、美白に対する意識の高まりにより、化粧料による美白効果だけでなく、飲食物として経口摂取することにより、内面美容を訴求する美白剤の提供が望まれている。しかしながら、経口摂取で美白効果を有するものとしては、ビタミンC製剤やチオール化合物等が知られているが、十分な効果を発揮していない。   In recent years, with the increasing awareness of whitening, it has been desired to provide a whitening agent that appeals not only to the whitening effect of cosmetics but also to oral intake as food and drink. However, vitamin C preparations, thiol compounds and the like are known as those having a whitening effect when taken orally, but do not exhibit sufficient effects.

また、経口摂取で美白効果を示す植物素材として、従来バラ科ピラカンタ属植物(特許文献1)、ブドウ種子エキス(非特許文献1)、ザクロエキス(非特許文献2)、アセロラ(非特許文献3)が公開および報告されているが、経口摂取による効果を確認した例はいまだ少ない。   In addition, as plant materials that show a whitening effect upon ingestion, conventional plants belonging to the genus Pyracantata (Patent Document 1), grape seed extract (Non-Patent Document 1), pomegranate extract (Non-Patent Document 2), acerola (Non-Patent Document 3) ) Has been published and reported, but there are still few examples of confirming the effects of ingestion.

特開平11−322775JP-A-11-322775 Pigment Cell Res, 16, 629(2003)Pigment Cell Res, 16, 629 (2003) Biosci Biotechnol Biochem, 69(12), 2368(2005)Biosci Biotechnol Biochem, 69 (12), 2368 (2005) 日本農芸化学会2006年度大会講演要旨集,p. 222 (2006)Abstracts of Annual Meeting of the Japanese Society for Agricultural Chemistry 2006, p. 222 (2006)

本発明の目的は、経口摂取で美白効果を飛躍的に高めることが出来る経口投与型美白剤を提供することにある。   An object of the present invention is to provide an oral administration type whitening agent capable of dramatically enhancing the whitening effect by ingestion.

本発明は、上記課題を解決するために本発明者等が鋭意研究を重ねた結果、サリドロサイドを有効成分として含む美白剤を経口摂取することにより、美白効果が奏せられることを見出し、更に本発明は、サリドロサイドを含有する植物からなる群から選ばれる少なくとも1種の植物の粉末、抽出物または該抽出物の粗精製物もしくは精製物を有効成分として含むことを特徴とする経口投与型美白剤を提供するものである。上記サリドロサイドを含有する植物とは例えばイワベンケイ属に属する植物である。   In order to solve the above problems, the present inventors have conducted extensive research and found that a whitening effect can be achieved by orally ingesting a whitening agent containing salidroside as an active ingredient. The invention comprises at least one plant powder selected from the group consisting of plants containing salidroside, an extract, or a crudely purified or purified product of the extract as an active ingredient. Is to provide. The plant containing salidroside is, for example, a plant belonging to the genus Iwabenkei.

本発明は、飲食物として経口摂取することにより色素沈着を抑制することができ、日焼け・シミ・ソバカス等を予防または治療し、優れた美白効果を有する経口投与型美白剤を提供するものである。また、サリドロサイドは生薬由来のものであるため、副作用が比較的少なく、長期間投与が可能である。   The present invention provides an orally-administered whitening agent that can suppress pigmentation when taken orally as a food and drink, prevents or treats sunburn, spots, freckles, etc., and has an excellent whitening effect. . Further, since salidroside is derived from herbal medicines, it has relatively few side effects and can be administered for a long time.

本発明の経口投与型美白剤は、上記したようにサリドロサイドを有効成分として含有するか、あるいはサリドロサイドを含有する植物からなる群から選ばれる少なくとも1種の植物の粉末、抽出物または該抽出物の粗精製物もしくは精製物を有効成分として含む。   The oral administration type whitening agent of the present invention contains salidroside as an active ingredient as described above, or at least one plant powder, extract or extract of the extract selected from the group consisting of plants containing salidroside A crude product or a purified product is contained as an active ingredient.

本発明の経口投与型美白剤の有効成分であるサリドロサイドは下記の構造式を有する。   Salidroside which is an active ingredient of the oral administration type whitening agent of the present invention has the following structural formula.

Figure 2008013440
Figure 2008013440

分子式及び分子量:C14H20O7、300.30
物理性状:片状結晶(酢酸エチル)、融点159〜60℃、〔α〕D 20−32.1°(C=1.26、水)。
NMR(D2O、DSS)δ 3.97(2H,d,J=7,-OCH2-), 2.88(2H,t,J=7,C−CH2−C), 6.82, 6.90, 7,13, 7.20(aromatic,4H),4.45(1H,d,J=8,糖1-H)。
Molecular formula and molecular weight: C 14 H 20 O 7 , 300.30
Physical properties: flake crystals (ethyl acetate), melting point 159-60 ° C., [α] D 20 −32.1 ° (C = 1.26, water).
NMR (D 2 O, DSS) δ 3.97 (2H, d, J = 7, -OCH 2- ), 2.88 (2H, t, J = 7, C-CH 2 -C), 6.82, 6.90, 7,13 , 7.20 (aromatic, 4H), 4.45 (1H, d, J = 8, sugar 1-H).

イワベンケイソウ科イワベンケイ属に属する植物としては、経口投与で美白作用を有する活性成分を含むものであればいかなる種類のものであってもよく、例えば紅景天(Rhodiola rosea)、高山紅景天(R. sachalinensis)、大花紅景天(R. crenulata)、四裂紅景天(R. quadrifida)、大紫紅景天(R. atropupurea)、雲南紅景天(R. yunnanensis)、長園紅景天(R. sorrestii)、紫緑紅景天(R. purpureoviridis)、長鞭紅景天(R. gelida)、条葉紅景天(R. linearfolia)、羽裂紅景天(R. pinnatifida)、浅緑紅景天(R. viridula)、異歯紅景天(R. heterodonta)、謝氏紅景天(R. semenovii)、黄萼紅景天(R. litvinovii)、優美紅景天(R. coccinea)等の1種または2種以上を使用することが出来、中でも紅景天(Rhodiola rosea)を使用するのが好ましい。   As the plant belonging to the genus Ichabenkei, which belongs to the genus Ichabenaceae, it may be of any kind as long as it contains an active ingredient having a whitening effect by oral administration. For example, Rhodiola rosea, Takayama Kokeiten ( R. sachalinensis), R. crenulata, R. quadrifida, R. atropupurea, R. yunnanensis, Chozoen Heaven (R. sorrestii), purple green scenic heaven (R. purpureoviridis), long whip scenic heaven (R. gelida), striped red scenic heaven (R. linearfolia), R. pinnatifida, light green R. viridula, R. heterodonta, R. semenovii, R. litvinovii, R. coccinea, etc. 1 type or 2 types or more can be used, and among them, it is preferable to use Rhodiola rosea.

上記イワベンケイ属に属する植物以外にも下記の植物はサリドロサイドを含有し、本発明の植物として利用可能である。
タチヤナギ(Salix triandra)(ヤナギ科)、コケモモ(Vaccinium vitis-idaea)(ツツジ科)、トウネズミモチ(Ligustrum lucidum)(モクセイ科)、レンギョウ(Forsythia suspensa)(モクセイ科)、Phillyrea latifolia(モクセイ科)、シマトネリコ(Fraxinus griffithii)(モクセイ科)、ウチワノキ(Abeliophyllum distichum)(モクセイ科)、ホミカ(Strychnos nux-vomica)(フジウツギ科)、ミツモウカ(Buddleja officinalis)(フジウツギ科)、ダイケットウ(Sargentodoxa cuneata)(アケビ科)、レモンバーベナ(Lippia triphylla)(クマツヅラ科)、サンゴジュ(Vibrunum awabuki)(スイカズラ科)、コガネバナ(Scutellaria baicalensis)(シソ科)、ウンシュウミカン(Citrus unshiu)(ミカン科)、ニクジュヨウ(Cistanche deserticola)または同属植物(ハマウツボ科)、ハマウツボ(Orobanche coerulescens)(ハマウツボ科)、テツコサン(Schisandra propinqua)(マツブサ科)、Castilleja chromosa(ゴマノハグサ科)、ジオウ(Rehmannia glutinosa)(ゴマノハグサ科)、ウンラン(Linaria japonica)(ゴマノハグサ科)、Lagochilus platicalyx(シソ科)、Phlomis spinidens(シソ科)、Cassinopsis ciliata(クロタキカズラ科)、ウラジロガシ(Quercus stenophylla)(ブナ科)、Quercus phillyreoides(ブナ科)、インヨウカク(Epimedium grandiflorum)(メギ科)、Epimedium koreanum(メギ科)。
In addition to the plants belonging to the genus Iwabenkei, the following plants contain salidroside and can be used as the plant of the present invention.
Salix triandra (Alanaceae), Cowberry (Vaccinium vitis-idaea) (Azalea), Ligustrum lucidum (Asteraceae), Forsythia suspensa (Asteraceae), Phillyrea latifolia (Asteraceae) Fraxinus griffithii (Apiaceae), Prickly pear (Abeliophyllum distichum) (Apiaceae), Homika (Strychnos nux-vomica) (Butaceae), Buddleja officinalis (Aureae cuneidae) ), Lemon Verbena (Lippia triphylla), Vibrunum awabuki (Rhizoaceae), Scutellaria baicalensis (Ciraceae), Citrus unshiu (Rutaceae), Cistanche deserticola or Cistanche deserticola Plants belonging to the same genus (Heroptera), Orobanche coerulescens), Schisandra propinqua (Brassaceae), Castilleja chromosa, Rehmannia glutinosa, Linaria japonica, Linx jaxonica, Lax , Phlomis spinidens (Lamiaceae), Cassinopsis ciliata (Polygonaceae), Vultures (Quercus stenophylla) (Beechaceae), Quercus phillyreoides (Epiaceae), Epimedium grandiflorum (Epiaceae), Epimedium koreanum.

上記植物の粉末化や抽出は常法によって行えばよい。抽出は、例えば上記植物の1種または2種以上を乾燥して刻み、または粉末状にして抽出溶媒を加え、冷浸または加熱することによって行うことが出来る。抽出溶媒としては、水、アルコール類、エーテル類、エステル類、ケトン類、ニトリル類、芳香族炭化水素類、ハロゲン化脂肪族炭化水素類の1種または2種以上の混合溶媒を使用することが出来る。   What is necessary is just to perform the powdering and extraction of the said plant by a conventional method. Extraction can be performed, for example, by drying one or two or more of the above plants and chopping them, or powdering them, adding an extraction solvent, and cooling or heating. As the extraction solvent, it is possible to use one or a mixture of two or more of water, alcohols, ethers, esters, ketones, nitriles, aromatic hydrocarbons, and halogenated aliphatic hydrocarbons. I can do it.

なお、本発明における抽出物とは、抽出液、該抽出液の希釈液もしくは濃縮液、該抽出物を乾燥して得られる乾燥物、または抽出エキスのいずれかをも意味するものとする。上記抽出物の粗精製および精製は常法によって行えばよく、例えば吸着剤による吸着および溶出、クロマトグラフィー等の公知の手段を適当に組み合わせて実施することが出来る。   The extract in the present invention means any one of an extract, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, or an extract. The above-mentioned extract may be roughly purified and purified by a conventional method, and can be carried out by appropriately combining known means such as adsorption and elution with an adsorbent, chromatography and the like.

以上のようにして得られる上記植物の1種または2種以上の粉末、抽出物、該抽出物の粗精製物および精製物は、後述する実施例から明かなように、内服で美白効果を有するため、経口投与型美白剤の有効成分として使用することが出来る。本発明の経口投与型美白剤は、生薬由来のものを有効成分としているため、副作用が比較的少なく、長期間の服用が可能であると考えられる。   One or more kinds of the above-obtained plant powder, extract, crudely purified product and purified product of the extract obtained as described above have a whitening effect in internal use, as will be apparent from Examples described later. Therefore, it can be used as an active ingredient of an oral administration type whitening agent. The oral administration type whitening agent of the present invention uses a crude drug-derived active ingredient as an active ingredient, so it is considered that it has relatively few side effects and can be taken for a long time.

本発明の経口投与型美白剤は、経口摂取可能な形態、例えば、粉末、散剤、顆粒剤、錠剤、カプセル剤などの剤型にすることが出来、またそれ以外常法に従い、例えば、菓子や清涼飲料水や主食に添加する等様々な使用形態の食品とすることが出来る。本発明の経口投与型美白剤が添加される食品には、上記美白剤である有効成分のほか、ビタミンC製剤やチオール化合物等の従来公知の美白効果を有するその他の成分を同時に配合してよく、更に必要に応じて通常食品に用いられる賦形剤、増量剤、甘味剤、香味剤、着色剤等の添加物を本発明の効果を損なわない範囲で適宜配合することが出来る。   The oral administration type whitening agent of the present invention can be in an ingestible form such as powder, powder, granule, tablet, capsule, etc. It can be made into a variety of usage forms such as adding to soft drinks and staple foods. In addition to the active ingredients that are the above-mentioned whitening agents, other ingredients having conventionally known whitening effects such as vitamin C preparations and thiol compounds may be blended in the food to which the oral administration type whitening agent of the present invention is added. Furthermore, additives such as excipients, extenders, sweeteners, flavoring agents, and coloring agents that are usually used in foods can be appropriately blended as necessary within the range not impairing the effects of the present invention.

以下、本発明を実施例によって説明する。但し、本発明の範囲は以下に示される実施例のみに限定されるものではない。   Hereinafter, the present invention will be described by way of examples. However, the scope of the present invention is not limited to only the examples shown below.

〔実施例〕
(マウス色素沈着抑制実験)
本発明は、紫外線照射で誘導されるマウス耳介色素沈着形成抑制効果の測定実験を行った。本発明は、このマウス耳介色素沈着に対する経口投与での抑制作用を検討したものである。
(1)実験動物
5週齢のDBA/2雄性マウスを1週間の予備飼育後、1群6匹として使用した。
〔Example〕
(Mouse pigmentation suppression experiment)
In the present invention, a measurement experiment of the inhibitory effect on mouse ear pigmentation formation induced by ultraviolet irradiation was performed. The present invention examines the inhibitory effect of oral administration on this mouse ear pigmentation.
(1) Experimental animals 5-week-old DBA / 2 male mice were used as 6 mice per group after 1 week of preliminary breeding.

(2)試料溶液の調製
紅景天100gに70%エタノール1000mlを加え、1時間加熱抽出を行い、その抽出液を濾過し、濾液を濃縮後凍結乾燥して、紅景天エキス末10gとした。このエキス末を常法に従い、サリドロサイド含量をHPLCにて測定したところ3.43%であった。
(2) Preparation of sample solution Add 100 ml of 70% ethanol to 100 g of red scenic heaven, heat extract for 1 hour, filter the extract, concentrate the filtrate and freeze-dry to 10 g of red scenic extract powder. . When the extract powder was measured for the salidroside content by HPLC according to a conventional method, it was 3.43%.

(3)色素沈着モデル
マウスに9日間、紅景天エキス末を1mg/匹、0.5mg/匹の割合で、サリドロサイドを紅景天エキス末1mg/匹に相当する34.3μg/匹の割合で胃内強制投与し、投与1時間後に6分間、総照射量0.09mJのUVBを照射した。UV照射群(対照群)にはmilliQ水、陽性対照群にはアスコルビン酸ナトリウム(300mg/kg)及びL−システイン(240mg/kg)を投与した。またUV非照射群(正常群)を設定し、milliQ水を投与した。10日目に耳介を採取し、背部側の耳介部皮膚を24穴プレート中で0.025M EDTAに浸して2時間37℃でインキュベートした。リン酸緩衝液で洗った後、新しい24穴プレートに換え、基質液(リン酸緩衝液に0.1%となるようにDL−DOPAを溶かしたもの)に浸して4時間37℃でインキュベートした。70%エタノール(30分)→90%エタノール(30分)→無水エタノール(一晩)→モレキュラーシーブ入り無水エタノール(30分)→キシレン(30分)→キシレン(30分)の順番に浸して脱水処理した。プレパラート上で組織を封入し、顕微鏡観察下で任意の5箇所を選び、面積あたりのDOPA陽性メラノサイト数を算出した。
(3) Pigmentation model The ratio of 34.3 μg / animal corresponding to 1 mg / animal of red ginseng extract powder at a ratio of 1 mg / animal and 0.5 mg / animal of red scenic extract powder to mice for 9 days. Intragastric forced administration was performed, and UVB with a total irradiation amount of 0.09 mJ was irradiated for 6 minutes one hour after the administration. MilliQ water was administered to the UV irradiation group (control group), and sodium ascorbate (300 mg / kg) and L-cysteine (240 mg / kg) were administered to the positive control group. In addition, a UV non-irradiated group (normal group) was set, and milliQ water was administered. On the 10th day, the auricle was collected, and the dorsal auricular skin was immersed in 0.025M EDTA in a 24-well plate and incubated at 37 ° C. for 2 hours. After washing with phosphate buffer, the plate was replaced with a new 24-well plate and immersed in a substrate solution ( DL- DOPA dissolved to 0.1% in phosphate buffer) and incubated at 37 ° C. for 4 hours. . 70% ethanol (30 minutes) → 90% ethanol (30 minutes) → absolute ethanol (overnight) → absolute ethanol with molecular sieve (30 minutes) → xylene (30 minutes) → xylene (30 minutes) Processed. The tissue was encapsulated on the preparation, arbitrary 5 locations were selected under a microscope, and the number of DOPA positive melanocytes per area was calculated.

色素沈着モデルの実験結果を図1に示した。なお、図1中の**はTukey−Kramer test(有意水準**p<0.01)により統計処理を行った場合、UV照射群に対し有意差が認められたものを示した。   The experimental results of the pigmentation model are shown in FIG. In addition, when ** in FIG. 1 was statistically processed by Tukey-Kramer test (significance level ** p <0.01), the thing by which the significant difference was recognized with respect to the UV irradiation group was shown.

図1に示す様にUV照射によりDOPA陽性メラノサイト数の著しい増加が認められ(UV照射群)、紅景天エキス末および、エキス末に含まれるサリドロサイド相当量はこのメラノサイト数の増加を用量依存的に有意に抑制した。紅景天エキス末のメラノサイト数を抑制する作用は、サリドロサイドの作用であることが確認された。陽性対照群においてもDOPA陽性メラノサイト数の増加を抑える傾向が認められたが有意ではなかった。   As shown in FIG. 1, a significant increase in the number of DOPA-positive melanocytes was observed by UV irradiation (UV irradiation group), and the amount of salidroside contained in red ginseng extract powder and the extract powder depended on the increase in the number of melanocytes in a dose-dependent manner. Was significantly suppressed. It was confirmed that the action of suppressing the number of melanocytes in the red bean extract powder is the action of salidroside. Even in the positive control group, a tendency to suppress the increase in the number of DOPA-positive melanocytes was observed, but it was not significant.

本発明の経口投与型美白剤は優れた美白効果を有し、かつ副作用がないので長期間の服用が可能であるから、産業上利用可能である。   Since the oral whitening agent of the present invention has an excellent whitening effect and has no side effects, it can be taken for a long period of time and can be used industrially.

紅景天エキス末およびサリドロサイドのマウス耳介色素沈着抑制作用を示すグラフA graph showing the effects of red ginseng extract powder and salidroside on mouse ear pigmentation

Claims (2)

下記の構造を有するサリドロサイドを有効成分として含むことを特徴とする経口投与型美白剤。
Figure 2008013440
An oral administration whitening agent comprising salidroside having the following structure as an active ingredient.
Figure 2008013440
サリドロサイドを含有する植物から選ばれる1種の植物の粉末、抽出物または該抽出物の粗精製物もしくは精製物を有効成分として含むことを特徴とする経口投与型美白剤。 An orally administrable whitening agent comprising a powder, an extract of a plant selected from plants containing salidroside, or a crudely purified or purified product of the extract as an active ingredient.
JP2006183126A 2006-07-03 2006-07-03 Orally administering type beautifully whitening agent Withdrawn JP2008013440A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006183126A JP2008013440A (en) 2006-07-03 2006-07-03 Orally administering type beautifully whitening agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006183126A JP2008013440A (en) 2006-07-03 2006-07-03 Orally administering type beautifully whitening agent

Publications (1)

Publication Number Publication Date
JP2008013440A true JP2008013440A (en) 2008-01-24

Family

ID=39070827

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006183126A Withdrawn JP2008013440A (en) 2006-07-03 2006-07-03 Orally administering type beautifully whitening agent

Country Status (1)

Country Link
JP (1) JP2008013440A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009263279A (en) * 2008-04-25 2009-11-12 Oriza Yuka Kk Elastase inhibitor
JP2013256448A (en) * 2012-06-11 2013-12-26 Kao Corp Whitening agent

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009263279A (en) * 2008-04-25 2009-11-12 Oriza Yuka Kk Elastase inhibitor
JP2013256448A (en) * 2012-06-11 2013-12-26 Kao Corp Whitening agent

Similar Documents

Publication Publication Date Title
US20240024403A1 (en) Compositions and Methods for Managing Weight
CN105452269B (en) Compositions and methods for joint health
KR101077523B1 (en) A composition comprising the extract of crude drug selected from Eriobotryae Folium and Dendropanax morbiferafor treating and preventing neuro-degenerative disease
EP3064209B1 (en) Composition comprising ginsenoside f2 for preventing or treating insulin resistance
JP2006016390A (en) Proanthocyanidin-containing composition
JP2023027253A (en) Novel ellagitannin and agent for oral application
JP2001064172A (en) Agent for preventing and treating disease caused by mutation of apc gene
TW201340977A (en) Des(rhamnosyl) acteoside-containing olive extract
JP2010132632A (en) Protein saccharification inhibitor
Deshpande et al. Phytosomes: A noval drug delivery system for phytoconstituents
JP2008013440A (en) Orally administering type beautifully whitening agent
KR20080096162A (en) Cosmetic composition for whitening skin
KR20170109703A (en) A pharmaceutical composition for preventing or treating cancer comprising fractions of herbal mixture extract
KR20040101598A (en) Active fraction having weight loss effects on Leprdb/Leprdb mice isolated from medicinal plants
KR102206882B1 (en) Composition for preventing or treating hearing loss comprising extract of leaves or stem of sweet potato
Mihailović et al. Silybin and Silymarin: Phytochemistry, bioactivity, and pharmacology
KR20170136785A (en) Composition for enhancing the bioavailability of fat-soluble vitamins
WO2015138135A1 (en) Compositions and methods for inhibition of triglyceride synthesis via synergistic combination of botanical formulations
KR20200014567A (en) A composition for improving, preventing and treating of liver diseases comprising Milk thistle
KR101892659B1 (en) Pharmaceutical composition or functional food containing malaxinic acid for improvement of insulin sensitivity
KR20130038526A (en) Essence using date extracts and red jinseng extracts and manufacturing method thereof
JP2002220333A (en) Skin-whitening agent for oral intake
KR20160104824A (en) Pharmaceutical composition for prevention or treatment of Parkinson&#39;s disease comprising herbal extract or fraction thereof
WO2005067954A1 (en) A pharmaceutical composition comprising the extract of sorbus amurensis koehne for treating or preventing cerebrovascular system disease
KR20220162233A (en) Anticancer composition comprising Youngia sonchifolia extract thereof

Legal Events

Date Code Title Description
A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20091006